Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of the 74 adult patients treated with the company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, defined as patients having an Apnea Hypopnea Index (“AHI”) score of less than five post-treatment. “We are not aware of any treatment for OSA where 28% of patients are restored post-treatment to AHI scores that are within normal limits and with the potential for no ongoing intervention. In a previous outside analysis of real-world data, which is pending publication, the number of patients who finished Vivos treatment with fully resolved OSA was one out of three,” said Vivos chairman and CEO Kirk Huntsman. “In that instance, patients were treated directly for their OSA by the company’s FDA cleared mRNA appliance, which is very similar to the DNA appliance, showing our latest data is consistent. Simply put, we believe this clinical data shows that our core technology is a game-changer for OSA sufferers who undergo the Vivos treatment. As we recently reported, 97% of patients reported they fully achieved their treatment goals. The dentists who treated these patients know this is a huge breakthrough, and pretty soon the rest of the world will too.”
To view the full press release, visit https://ibn.fm/WEuzr
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape, and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
